access-principles-1access-principles-2access-principles-3backcarrierdevelopmentease_of_administrationexportimplantableinjectablenon-implantablenon_carriernon_injectableother_featuresprintroute_of_administrationtherapeutic_areatype_of_tech
Back

Drug name

Last update: Aug 2026

VH-280 (VH-4004280)

Developer(s)

ViiV Healthcare
export_notes

Drug information

Drug's link(s)

Not provided

Generic name

Not provided

Brand names

investigational - investigation was discontinued by ViiV

Compound type

Small molecule

Drug class/category

Capsid inhibitor

Summary

VH4004280 (also known as VH-280 or GSK4004280) is an investigational oral HIV-1 capsid inhibitor. This novel antiretroviral targets the HIV-1 capsid protein, a crucial component involved in multiple stages of the viral lifecycle. VH-280 functions by binding to a pocket formed between adjacent capsid proteins within the mature capsid hexamer. This interaction disrupts essential viral processes. Preclinical studies have demonstrated that VH-280 exhibits potent antiviral activity, with half-maximal effective concentrations (EC50 values) in the picomolar range against a broad spectrum of HIV-1 laboratory strains and clinical isolates. Its mechanism is understood to be multi-stage, impacting both early and late phases of the HIV-1 life cycle.

Approval status

investigational

Regulatory authorities

investigational

Therapeutic area(s)

  • HIV
Use case(s)
  • Pre-Exposure Prophylaxis (PrEP)
  • Treatment
  • Prevention

Administration route

Oral, Subcutaneous, Intramuscular,

Associated long-acting platforms

Oral solid form

Use of drug

Ease of administration
  • Self-administered
Frequency of administration
  • Other/Variable/Unknown : to be determined
User acceptance
Not provided

Dosage

Available dose and strength

to be determined

Maximum dose

to be determined

Recommended dosing regimen

to be determined

Additional comments

Not provided

Dosage link(s)

Not provided

Associated compounds, formulations and regimens

Not provided

Associated technologies

Not provided

Additional information

Not provided

Developer(s)

ViiV Healthcare
Originator
United Kingdom

ViiV Healthcare

Drug structure

Scale-up and manufacturing prospects

Scale-up prospects

Detailed manufacturing information is not currently available for this compound.

Tentative equipment list for manufacturing

Detailed manufacturing information is not currently available for this compound.

Manufacturing

Detailed manufacturing information is not currently available for this compound.

Specific analytical instrument required for characterization of formulation

Detailed manufacturing information is not currently available for this compound.

Excipients & delivery device(s)

Proprietary excipients used

Not provided

Novel excipients or existing excipients at a concentration above Inactive Ingredient Database (IID) for the specified route of administration

Not provided

Residual solvents used

Not provided

Delivery device(s)

Not provided

Safety, Efficacy and Evidence Summary

Safety

Not provided

Efficacy

Not provided

Evidence Summary

Not provided

References and relevant studies

Not provided

There are either no relevant patents or these were not yet submitted to LAPaL

Please be informed that this site uses cookies. Learn more

Allow cookies